CN110710678A - 一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法 - Google Patents
一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法 Download PDFInfo
- Publication number
- CN110710678A CN110710678A CN201911144450.7A CN201911144450A CN110710678A CN 110710678 A CN110710678 A CN 110710678A CN 201911144450 A CN201911144450 A CN 201911144450A CN 110710678 A CN110710678 A CN 110710678A
- Authority
- CN
- China
- Prior art keywords
- parts
- donkey
- nourishing
- hide gelatin
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 55
- 239000008280 blood Substances 0.000 title claims abstract description 55
- 210000003734 kidney Anatomy 0.000 title claims abstract description 54
- 210000004185 liver Anatomy 0.000 title claims abstract description 54
- 108010010803 Gelatin Proteins 0.000 title claims abstract description 44
- 229920000159 gelatin Polymers 0.000 title claims abstract description 44
- 239000008273 gelatin Substances 0.000 title claims abstract description 44
- 235000019322 gelatine Nutrition 0.000 title claims abstract description 44
- 235000011852 gelatine desserts Nutrition 0.000 title claims abstract description 44
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 35
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 31
- 210000005036 nerve Anatomy 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 48
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 48
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 31
- 241000208340 Araliaceae Species 0.000 claims abstract description 30
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 30
- 235000008434 ginseng Nutrition 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 241001646828 Platostoma chinense Species 0.000 claims abstract description 26
- 241000237502 Ostreidae Species 0.000 claims abstract description 20
- 235000020636 oyster Nutrition 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000000813 microbial effect Effects 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 18
- 238000009924 canning Methods 0.000 claims description 17
- 230000001954 sterilising effect Effects 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 14
- 108010052008 colla corii asini Proteins 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 240000006439 Aspergillus oryzae Species 0.000 claims description 6
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 6
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000003292 glue Substances 0.000 claims description 5
- 230000000415 inactivating effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 108091005658 Basic proteases Proteins 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000001471 micro-filtration Methods 0.000 claims description 4
- 238000001728 nano-filtration Methods 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 230000001877 deodorizing effect Effects 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 25
- 230000007812 deficiency Effects 0.000 abstract description 24
- 235000013305 food Nutrition 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 13
- 235000019640 taste Nutrition 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 52
- 239000000243 solution Substances 0.000 description 29
- 238000012360 testing method Methods 0.000 description 23
- 239000008213 purified water Substances 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 208000031971 Yin Deficiency Diseases 0.000 description 10
- 238000003304 gavage Methods 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010033557 Palpitations Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 230000002936 tranquilizing effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010041497 Spermatorrhoea Diseases 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000251511 Holothuroidea Species 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 206010013789 Dry throat Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UICBCXONCUFSOI-UHFFFAOYSA-N n'-phenylacetohydrazide Chemical compound CC(=O)NNC1=CC=CC=C1 UICBCXONCUFSOI-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000231176 Boschniakia rossica Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OGZGXRDCONAFML-UHFFFAOYSA-N NN.CC(=O)C1=CC=CC=C1 Chemical compound NN.CC(=O)C1=CC=CC=C1 OGZGXRDCONAFML-UHFFFAOYSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 208000019667 acute articular rheumatism Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- RKLXDNHNLPUQRB-TVJUEJKUSA-N chembl564271 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]2C(C)SC[C@H](N[C@@H](CC(N)=O)C(=O)NC(=O)[C@@H](NC2=O)CSC1C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(=C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H]1NC(=O)C(=C\C)/NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)[C@H]3N[C@@H](CC(C)C)C(=O)NC(=O)C(=C)NC(=O)CC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C5=CC=CC=C5NC=4)CSC3)C(O)=O)C(C)SC2)C(C)C)C(C)SC1)C1=CC=CC=C1 RKLXDNHNLPUQRB-TVJUEJKUSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 108010082567 subtilin Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
Abstract
本发明公开了一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法,属于海洋功能食品技术领域。本发明的海洋多肽阿胶膏组成为:水55‑74份,阿胶9‑15份,鲍鱼低聚肽4‑12份,牡蛎低聚肽4‑10份,蛹虫草3‑8份,人参2‑5份,酸枣仁2‑10份,仙草2‑5。本发明滋补肝肾、养血安神海洋多肽阿胶膏,以传统中医理论为依据,配方遵循君臣佐使的组方原则,味少而精,温而不燥,补而不腻,既适合女性养血补虚,也适合男性肝肾亏虚,同时通过现代工艺技术,制成即食膏,食用方便,口感好,可以作为各类人群日常滋补食用。本发明通过微生物复合超声酶解制备的鲍鱼低聚肽分子量小,易吸收,营养物质保留完全。
Description
技术领域
本发明属于海洋功能食品技术领域,具体涉及一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法。
背景技术
肝肾是人体的两大重要器官,肝肾健康直接影响人体整体健康状况。中医中所指肝肾阴虚,是由于肾阴虚影响了肝阴不足或是肝阴浩劫导致的肾阴的亏损。肝肾的阴虚是基于肝肾的经血不足的表现,肝肾阴液亏虚,虚热内扰,以头晕目眩、眼干、易疲乏、肢体的麻木皮肤的瘙痒、口燥、咽干、失眠多梦、胁肋部的隐痛、遗精、腰酸、腰膝酸软、耳鸣,不孕、遗精、舌红苔少,女子月经量少等为主要表现,多由久病劳伤,或温热病邪耗伤肝阴及肾阴,或先天票赋不足,肾阴亏虚而及肝阴不足,形成肝肾阴虚。
众所周知,西药治疗针对性较强,作用范围较小,而滋补作用并不明显,并不适合肝肾阴虚患者长期使用,而中医,尤其是“药食同源”对肝肾阴虚的治疗有独到之处。“药食同源”即“医食同源,药食同根”,体现了食物在保健和治疗方面的功能,药食同源中药兼具了丰富的营养价值和药用价值。古代本草,尤其是食物类本草著作,记载了大量的“药食两用”中药材,同时根据现代功能学、毒理学等研究结果,卫计委(原卫生部)颁布了“按照传统既是食品又是药品物品”名单,进一步规范了药食同源中药的使用。近年来,对药食同源中药的功能报道越来越多。
传统的中药食用方法,往往需要长时间煎煮,对火候和时间要求较繁琐,口感苦涩,因此,以传统中医理论为指导,通过现代工艺技术,以现代营养学研究为理论基础,研究口感好、营养均衡、易吸收、作用效果明显、可长期食用的功能食品成为目前食品工业研究的热点。
发明内容
针对现有技术中存在的问题,本发明的目的在于提供一种食用方便、温和滋补、营养丰富,且具有滋补肝肾、养血安神功能的海洋多肽阿胶膏及其制备方法。
为达到以上目的,本发明采取的技术方案如下:
一种滋补肝肾、养血安神海洋多肽阿胶膏,由以下组分按重量份数制备而成:水55-74份,阿胶9-15份,鲍鱼低聚肽4-12份,牡蛎低聚肽4-10份,蛹虫草3-8份,人参2-5份,酸枣仁2-10份,仙草2-5份。
在上述方案的基础上,所述滋补肝肾、养血安神海洋多肽阿胶膏,由以下组分按重量份数制备而成:
水59份,阿胶12份,鲍鱼低聚肽6份,牡蛎低聚肽6份,蛹虫草4份,人参4份,酸枣仁6份,仙草3份。
在上述方案的基础上,所述鲍鱼低聚肽由以下方法制备而成:
①原料预处理:将整鲍鱼粉碎至10-20目,加入2-3倍量纯净水,得鲍鱼匀浆液,备用;
②微生物发酵:取步骤①制备的鲍鱼匀浆液,按10-20:1:1的质量比加入复合菌液、葡萄糖;搅拌均匀,调节pH至4.5-7.5,保持温度28-32℃,发酵12-24h,得鲍鱼发酵液,备用;
③超声酶解:向步骤②得到的鲍鱼发酵液中加入5-8倍量纯净水,NaOH调节pH至8.0-9.0,加入初始处理鲍鱼1%-2%倍量的复合碱性蛋白酶,加热升温至40-60℃,超声功率为500-700W,保温搅拌酶解3-5h,离心过滤收集酶解液,备用;
④灭菌、灭酶:将步骤③的酶解液煮沸15-20min灭菌、灭酶后进行0.5~1μm微滤膜过滤,去掉大分子杂质、细菌、霉菌,收集滤液,备用;
⑤脱色脱腥:将步骤④的滤液利用10~20nm纳滤膜过滤,去掉色素、蛋白等,滤液添加2-3%(w/v)812目颗粒活性炭脱腥处理,脱碳后收集液相,得精制液备用;
⑥浓缩干燥:将步骤⑤得到的精制液浓缩至质量分数30-40%,喷雾干燥,制得鲍鱼低聚肽。
在上述方案的基础上,所述步骤②中的复合菌液为米曲霉种子液5-8份、枯草芽孢杆菌菌液2-5份;所述米曲霉种子液中的菌含量≥3×108cfu/mL,所述枯草芽孢杆菌菌液中的菌含量≥3×108cfu/mL。
上述滋补肝肾、养血安神海洋多肽阿胶膏的制备方法,步骤如下:
1)原料粉碎、浸泡:按组分称取蛹虫草、人参、酸枣仁、仙草,分别粉碎至10-20目,加入到6-10倍纯净水中浸泡5-10h;
2)提取:将步骤1)浸泡后的蛹虫草、人参、酸枣仁、仙草放入提取罐中,加热到80-100℃,提取1-1.5h,过滤得第一次提取液;滤渣加入5-8倍纯净水,加热到80-100℃,提取1-1.5h,过滤得第二次提取液;
3)浓缩定容:合并步骤2)两次提取液,于浓缩罐中浓缩至初始药材质量分数为7-23%,得定容液,备用;
4)提取液熬胶:取阿胶加入到步骤3)制备的提取定容液中,煮沸,搅拌熬煮10-15min;
5)配料制膏:按组分将鲍鱼低聚肽、牡蛎低聚肽混合均匀,缓慢加入到步骤4)的熬煮液中,边加入边搅拌,完全加入后继续搅拌15-20min,过程保温在80-99℃;
6)罐装灭菌:将步骤5)得到的膏液进行罐装,罐装温度保持在80-95℃,罐装量为容器的90-95%,密封,恒温20-30min进行灭菌;
7)冷却成型:冷却至常温;
8)包装。
本发明滋补肝肾、养血安神海洋多肽阿胶膏的传统中医组方原理如下:
a)鲍鱼:其味甘、咸,性平,归肺、肝、肾经,滋阴清热,益精明目,养血柔肝,调经通乳,润燥开胃,利肠通淋。用于劳热骨蒸,咳嗽,青盲内障,月经不调,崩漏,带下,产后缺乳,淋浊,肾虚小便频数,大便燥结。
b)牡蛎(肉):其味甘、咸,性平、微寒,归心、脾、肝、肾经,滋阴生津,养血安神、调中补虚,益智聪脑,软坚消肿,清虚热,消丹毒,美颜润肤。用于虚损,贫血,佝偻病,智弱,盗汗,梦遗滑精。烦热失眠,心神不安,头晕目眩,中风,经血过多,崩漏,瘰疬,淋巴结节,甲状腺肿瘤,丹毒,牙龈肿痛,皮肤黧黑、粗糙,面斑、面多皱纹以及多种肿瘤的辅助治疗。
c)阿胶:阿胶始于秦汉,至今已有2000多年的历史了,为传统的滋补、补血上品。明代李时珍在《本草纲目》中记载:阿胶,本经上品。弘景曰:出东阿,故名阿胶。
其味甘、性平。归肺、肝、肾经。补血滋阴,润燥,止血。用于血虚萎黄,眩晕心悸,肌痿无力,心烦不眠,虚风内动,肺燥咳嗽,劳嗽咯血,吐血尿血,便血崩漏,妊娠胎漏。
d)蛹虫草:又称北冬虫夏草、北虫草、蛹草,俗名不老草,是现代珍稀中草药。《本草纲目》中指出,蝉花能主治“小儿天吊惊痫,夜啼,心悸”。研究表明蛹虫草具有与冬虫夏草极相似的作用,无毒副作用,可以作为冬虫夏草的代用品。
e)人参:人参甘、微苦,微温,归心、肺、脾经。大补元气,补脾益肺,生津止渴,安神益智。人参在《神农本草经》中被列为上品药物,具有“多服久服不伤身、轻身益气不老延年”的作用。临床用于:①用于气虚欲脱,脉微欲绝的危重症候;②用于肺气虚弱得短气喘促,懒言声微,脉虚自汗等证;③用于脾气不足的倦怠乏力,食少便溏等证;④用于热病气津两伤之身热口渴及消渴等证;⑤用于气血亏虚的心悸,失眠,健忘等证。
f)酸枣仁:甘、酸,平。归肝、胆、心经。功效为养心补肝,宁心安神,敛汗,生津。临床用于:①虚烦不眠,惊悸多梦;②体虚多汗;③津伤口渴。
g)仙草:又名仙人草、凉粉草,味甘淡,性凉。入脾、肾经。具有清暑,解热利水的功能。主治:中暑、热毒、消渴、高血压、肾脏病、糖尿病、关节肌肉疼痛、淋病、急性风湿性关节炎、感冒、黄疸,急性肾炎、泄泻、痢疾等。
鲍鱼,归肺、肝、肾经,滋阴补精,益精明目,养血柔肝;牡蛎(肉),归心、脾、肝、肾经,补肾精不足,养血安神、调中补虚;二者为君,滋阴养血、补肾填精。以阿胶和血滋阴、除风润燥、化痰清肺;以人参补益元气,可扶正固本,补脾益肺;以蛹虫草,补肾益肺、健脾安神;三味为臣,益气养血。酸枣仁,养心补肝,宁心安神,敛汗,生津;仙草清热利湿、凉血解毒,清热有助于鲍鱼肽、牡蛎肽、人参等温补不上火,凉血有助于阿胶补血;二者为佐。以上诸味合用,共奏补肾填精、固本培元、益气养血、补虚安神之效。
本发明滋补肝肾、养血安神海洋多肽阿胶膏的现代营养学组方原理如下:
研究表明,人体中大多活性物质都是以肽的形式存在,生物活性肽(Bioactivepeptides)是一类对机体生命活动有益且具有特殊生理功能的肽类化合物,由两个或两个以上氨基酸通过肽键连接而成,易吸收,来源广泛,具有抗疲劳、抗肿瘤、抗氧化、免疫调节、降低血糖血脂、调节血压、抑菌及促伤口愈合等多种生理活性,而其中,海洋生物活性肽是海洋生物免疫系统长期进化而来的一类蛋白类分子,因其具有的功能多样、来源广泛、特异性强、毒副作用小等优势,已逐渐成为21世纪研究的热点,已被广泛用于食品、化妆品、生物医药等领域。
协同作用是活性物质之间的一种常见反应,早在20世纪80年代,人们就发现蛋白质水解产物与其它物质存在不同程度的协同作用,尤其是食品,作为一种复杂的体系,成分多样,不同成分间可能存在一定协同作用,若添加比例适当,可以提升整个食品的的功效。因此,本发明利用海洋多肽、阿胶胶原、中药提取物多糖、皂苷、黄酮等协同作用,在现代营养学基础上达到滋补养生效果。
本发明相对于现有技术具有如下效果:
1、本发明提供的一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法,以传统中医理论为依据,配方遵循君臣佐使的组方原则,全方以抗疲劳、抗衰老、助睡眠为目的,味少而精,温而不燥,补而不腻,既适合女性养血补虚,也适合男性肝肾亏虚。
2、本发明通过微生物复合超声酶解制备鲍鱼肽,通过微生物发酵的方式产生多种作用酶以及枯草菌素、多粘菌素、制霉菌素、短杆菌肽等活性次级代谢产物,并通过微滤、纳滤的方式分离提纯,去除杂质、色素、脂肪、蛋白等大分子物质,保留小分子肽、多糖、有机酸、氨基酸、矿物质以及微生物次级代谢产物等活性物质,分子量小,易吸收,营养物质保留完全。
3、本发明以现代营养学为理论基础,通过现代工艺技术,制成即食膏,食用方便,口感好,同时依据多种科学研究结果佐证产品具有功效性,在功能改善上具备靶向性。多肽、氨基酸、多糖、虫草素、皂苷、黄酮等多种现代功效成分相互协同作用,增强产品的功效。
4、组方产品均为食品或药食同源中药材,食用更安全,无毒副作用。
具体实施方式
在本发明中所使用的术语,除非有另外说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实施例,并参照数据进一步详细的描述本发明。以下实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
实施例1
一种鲍鱼低聚肽的制备方法,步骤为:原料预处理→微生物发酵→超声酶解→灭菌、灭酶→脱色脱腥→浓缩干燥。
①原料预处理:将整鲍鱼粉碎至20目,加入2倍量纯净水,得鲍鱼匀浆液,备用;
②微生物发酵:取步骤①制备的鲍鱼匀浆液、步骤2)制备的复合菌液、葡萄糖,按质量比10:1:1的比例倒入发酵缸中,搅拌均匀,调节pH至6.0,保持温度30℃,发酵12h,得鲍鱼发酵液;
③超声酶解:将步骤②得到的的鲍鱼发酵液加入8倍量纯净水,4M NaOH调节pH至8.0,加入初始处理鲍鱼1%倍量的复合碱性蛋白酶,加热升温至50℃,超声功率为500W,保温搅拌酶解4h,离心过滤收集酶解液,备用;
④灭菌、灭酶:将步骤③的酶解液煮沸15min,进行1μm微滤膜过滤,去掉大分子杂质、细菌、霉菌,收集滤液,备用;
⑤脱色脱腥:将步骤④的滤液利用15nm纳滤膜过滤,去掉色素、蛋白等,滤液添加3%(w/v)812目颗粒活性炭脱腥处理,脱碳后收集液相,得精制液备用;
⑥浓缩干燥:将步骤⑤得到的精制液浓缩至质量分数35%,喷雾干燥,制得鲍鱼低聚肽粉末。
在上述方案的基础上,所述步骤②中的复合菌液为米曲霉种子液6份、枯草芽孢杆菌菌液4份;所述米曲霉种子液中的菌含量≥3×108cfu/mL,所述枯草芽孢杆菌菌液中的菌含量≥3×108cfu/mL。
所述鲍鱼低聚肽提取率为10.2%,低聚肽含量为62.8%,其中分子量1000Da以下的蛋白质水解物含量为95%。所述菌种购自北京万佳首化生物科技有限公司;所述复合碱性蛋白酶购自山东西唐生物科技有限公司。
实施例2
一种滋补肝肾、养血安神海洋多肽阿胶膏,由以下重量百分比组成:纯净水71份,阿胶9份,鲍鱼低聚肽5份,牡蛎低聚肽4份,蛹虫草3份,人参3份,酸枣仁2份,仙草3份。所述鲍鱼低聚肽为实施例1所制备的鲍鱼低聚肽;所述牡蛎低聚肽采购自大连深蓝肽科技研发有限公司(提取比例约10:1);所述阿胶采购自东阿阿胶;所述蛹虫草采购自江苏康能生物工程股份有限公司;所述人参、仙草、酸枣仁采购自湖北聚瑞中药饮片有限公司。
1)原料粉碎、浸泡:按组分称取蛹虫草、人参、酸枣仁、仙草,分别粉碎至20目,加入到6倍纯净水中浸泡8h;
2)提取:将步骤1)浸泡后的蛹虫草、人参、酸枣仁、仙草放入提取罐中,加热到100℃,提取1h,过滤得第一次提取液;滤渣加入5倍纯净水,加热到100℃,提取1h,过滤得第二次提取液;
3)浓缩定容:合并步骤2)两次提取液,于浓缩罐中浓缩至100份,其中初始药材质量分数为11%,得定容液,备用;
4)提取液熬胶:取阿胶加入到步骤3)制备的提取定容液中,煮沸,搅拌熬煮15min;
5)配料制膏:按组分将鲍鱼低聚肽、牡蛎低聚肽混合均匀,缓慢加入到步骤4)的熬煮液中,边加入边搅拌,完全加入后继续搅拌20min,过程保温在90℃;
6)罐装灭菌:将步骤5)得到的膏液进行罐装,罐装温度保持在90℃,罐装量为容器的90%,密封,恒温30min进行灭菌;
7)冷却成型:冷却至常温;
8)包装。
实施例3
一种滋补肝肾、养血安神海洋多肽阿胶膏,由以下重量百分比组成:纯净水61份,阿胶12份,鲍鱼低聚肽4份,牡蛎低聚肽4份,蛹虫草5份,人参4份,酸枣仁8份,仙草2份。所述鲍鱼低聚肽为实施例1所制备的鲍鱼低聚肽;所述牡蛎低聚肽采购自大连深蓝肽科技研发有限公司(提取比例约10:1);所述阿胶采购自东阿阿胶;所述蛹虫草采购自亳州市三义堂有限责任公司;所述人参、仙草、酸枣仁采购自湖北聚瑞中药饮片有限公司。
1)原料粉碎、浸泡:按组分称取蛹虫草、人参、酸枣仁、仙草,分别粉碎至20目,加入到8倍纯净水中浸泡10h;
2)提取:将步骤1)浸泡后的蛹虫草、人参、酸枣仁、仙草放入提取罐中,加热到95℃,提取1.5h,过滤得第一次提取液;滤渣加入5倍纯净水,加热到100℃,提取1h,过滤得第二次提取液;
3)浓缩定容:合并步骤2)两次提取液,于浓缩罐中浓缩至100份,其中初始药材质量分数为19%,得定容液,备用;
4)提取液熬胶:取阿胶加入到步骤3)制备的提取定容液中,煮沸,搅拌熬煮15min;
5)配料制膏:按组分将鲍鱼低聚肽、牡蛎低聚肽混合均匀,缓慢加入到步骤4)的熬煮液中,边加入边搅拌,完全加入后继续搅拌15min,过程保温在95℃;
6)罐装灭菌:将步骤5)得到的膏液进行罐装,罐装温度保持在90℃,罐装量为容器的90%,密封,恒温25min进行灭菌;
7)冷却成型:冷却至常温;
8)包装。
实施例4
一种滋补肝肾、养血安神海洋多肽阿胶膏,由以下重量百分比组成:纯净水59份,阿胶12份,鲍鱼低聚肽6份,牡蛎低聚肽6份,蛹虫草4份,人参4份,酸枣仁6份,仙草3份。所述鲍鱼低聚肽为实施例1所制备的鲍鱼低聚肽;所述牡蛎低聚肽采购自大连深蓝肽科技研发有限公司(提取比例约10:1);所述阿胶采购自东阿阿胶;所述蛹虫草采购自亳州市三义堂有限责任公司;所述人参、仙草、酸枣仁采购自湖北聚瑞中药饮片有限公司。
1)原料粉碎、浸泡:按组分称取蛹虫草、人参、酸枣仁、仙草,分别粉碎至10目,加入到8倍纯净水中浸泡10h;
2)提取:将步骤1)浸泡后的蛹虫草、人参、酸枣仁、仙草放入提取罐中,加热到95℃,提取1.5h,过滤得第一次提取液;滤渣加入6倍纯净水,加热到100℃,提取1.5h,过滤得第二次提取液;
3)浓缩定容:合并步骤2)两次提取液,于浓缩罐中浓缩至100份,其中初始药材质量分数为17%,得定容液,备用;
4)提取液熬胶:取阿胶加入到步骤3)制备的提取定容液中,煮沸,搅拌熬煮15min;
5)配料制膏:按组分将鲍鱼低聚肽、牡蛎低聚肽、混合均匀,缓慢加入到步骤4)的熬煮液中,边加入边搅拌,完全加入后继续搅拌20min,过程保温在95℃;
6)罐装灭菌:将步骤5)得到的膏液进行罐装,罐装温度保持在95℃,罐装量为容器的90%,密封,恒温25min进行灭菌;
7)冷却成型:冷却至常温;
8)包装。
以上所述仅为本发明的优选实施例,并非因此即限制本发明的专利保护范围,凡是运用本发明说明书内容所作的等效变换,直接或间接运用在其他相关的技术领域,均同理包括在本发明的保护范围内。
肝肾抗氧化功效、补血作用及安全性评价:
试验动物:健康SPF级ICR雄性小鼠110只,体重18-23g±2g,动物房适应性喂养2天后,按体重随机分为11组,每组10只,其中1组为正常组,2~11组为模型组,进行血虚模型建立。屏障环境饲养。
血虚小鼠模型建立(乙酰苯肼溶血法):小鼠于第1、4、7天进行皮下注射2%乙酰苯肼生理盐水水溶液,剂量分别为200、100、100mg/kg。
供试物:清洁级全价鼠颗粒饲料,蒸馏水;
供试物A:阿胶12份,鲍鱼低聚肽6份,牡蛎低聚肽6份,蛹虫草4份,人参4份,酸枣仁6份,仙草3份;
供试物B:阿胶12份,玉米淀粉12份,蛹虫草4份,人参4份,酸枣仁6份,仙草3份;
供试物C:阿胶12份,鲍鱼低聚肽6份,牡蛎低聚肽6份,玉米淀粉17份;
灌胃剂量选择:本发明海洋多肽阿胶膏推荐成人服用量为100g/人·日,折合生药量为41g/人·日,成人体重按60kg计算,正常服用剂量0.68g/kg·bw;每只小鼠每天灌胃量按0.2mL/10g·d计算,分别称取3.39g、16.95g、33.89g各供试物内容物,溶解于100mL蒸馏水中,分别制成低剂量0.68g/kg·bw,中等剂量3.40g/kg·bw,高剂量6.80g/kg·bw灌胃物。每天经口灌胃1次,连续灌胃30天后测各项指标。实验期间各组小鼠正常摄食,自由饮水。
试验分组:
1正常对照组:灌胃等剂量蒸馏水;
2模型对照组:灌胃等剂量蒸馏水;
3低剂量组A:灌胃供试物A低剂量0.68g/kg·bw;
4低剂量组B:灌胃供试物B低剂量0.68g/kg·bw;
5低剂量组C:灌胃供试物C低剂量0.68g/kg·bw;
6中剂量组A:灌胃供试物A中剂量3.40g/kg·bw;
7中剂量组B:灌胃供试物B中剂量3.40g/kg·bw;
8中剂量组C:灌胃供试物C中剂量3.40g/kg·bw;
9高剂量组A:灌胃供试物A高剂量6.80g/kg·bw;
10高剂量组B:灌胃供试物B高剂量6.80g/kg·bw;
11高剂量组C:灌胃供试物C高剂量6.80g/kg·bw;
检测指标及方法:
1)血常规:各组于末次给药后1.5h眼底静脉丛采血,采用全自动血液分析仪测定血常规,主要包括外周血中白细胞(WBC)、红细胞(RBC)、血红蛋白(HGB)和红细胞压积(HCT)4项指标。
2)免疫器官/体重比值:小鼠脱颈椎处死后取胸腺和脾脏称重,按公式计算胸腺指数和脾脏指数,胸腺指数=胸腺重(mg)/鼠重(g);脾脏指数=脾重(mg)/鼠重(g)。
3)肝肾抗氧化活性测定:
a)组织匀浆制备:小鼠脱颈椎处死后取肝脏和肾脏,取组织块1g,加入冷生理盐水研磨成10%匀浆,3000r/min离心12min,上清液置4℃冰箱中待用;
b)超氧化物歧化酶(SOD)活性:将a)中匀浆液稀释成1%匀浆,黄嘌呤氧化酶法测定;
c)谷胱甘肽过氧化物酶(GSH-PX)活性:肝用1%匀浆,肾用10%匀浆,酶法测定;
d)丙二醛(MDA)含量:10%匀浆,用TBA比色法测定。
结果分析:
表1本发明对血虚小鼠模型血常规的影响
注:与正常对照组相比▲p<0.05,▲▲p<0.01;与模型对照组相比*p<0.05,**p<0.01。
由以上表1结果表明,与模型对照组相比,本发明低剂量组A对降低的RBC、HGB、HCT有显著的升高作用;中剂量组A对升高的WBC有显著降低作用,对降低的RBC、HGB有极显著的升高作用,对降低的HCT有显著的升高作用;高剂量组A对升高的WBC有极显著降低作用,对降低的RBC、HGB、HCT有极显著的升高作用,说明本发明是通过降低WBC的同时升高RBC、HGB、HCT来发挥补血作用。同时供试物B中剂量和高剂量、供试物C中剂量和高剂量也具有一定的补血作用,但作用效果均低于供试物A;表明本发明各配伍组成具有协同增效作用。
表2本发明对血虚小鼠模型免疫器官的影响
实验组 | 胸腺指数(mg/g) | 脾脏指数(mg/g) |
正常对照组 | 3.56±0.74 | 5.68±0.25 |
模型对照组 | 2.19±0.34<sup>▲▲</sup> | 26.43±0.88<sup>▲▲</sup> |
低剂量组A | 2.87±0.92 | 19.43±0.83* |
低剂量组B | 2.68±0.56 | 20.17±0.37 |
低剂量组C | 2.56±0.03 | 21.98±0.89 |
中剂量组A | 3.22±0.21** | 17.60±0.27* |
中剂量组B | 3.04±0.77* | 18.23±0.64* |
中剂量组C | 2.96±0.94* | 19.67±0.27* |
高剂量组A | 3.44±0.74** | 15.67±0.43** |
高剂量组B | 3.21±0.39** | 16.98±0.62** |
高剂量组C | 3.07±0.85* | 17.67±0.06* |
注:与正常对照组相比▲▲p<0.01;与模型对照组相比*p<0.05,**p<0.01。
由上述表2结果表明,与模型对照组相比,本发明低中剂量组A对降低的胸腺指数有极显著的升高作用,对升高的脾脏指数有显著的降低作用;高剂量组A对胸腺指数和脾脏指数均有极显著的影响,说明本发明可以促进胸腺免疫作用以及对乙酰苯肼造成的脾脏肿大有显著的恢复作用。同时供试物B中剂量和高剂量、供试物C中剂量和高剂量对胸腺、脾脏也具有一定作用,各配伍协同后对免疫器官的作用更大。
表3本发明对血虚小鼠模型肝肾抗氧化活性的影响
注:与正常对照组相比▲p<0.05,▲▲p<0.01;与模型对照组相比*p<0.05,**p<0.01。
由以上表3结果表明,与正常对照相比,乙酰苯肼处理会降低肝、肾SOD活性及GSH-PX活性,升高MDA含量,即肝肾中脂质过氧化程度升高。与模型对照组相比,各供试物均能升高肝肾中SOD活性及GSH-PX活性,降低肝肾中MDA含量,且随着剂量的增加作用效果增加,其中,供试物A的效果最为显著。这说明本发明通过复配的方式,可以显著提高肝肾的抗氧化活性。
从以上试验结果可以看出,本发明海参多肽阿胶膏中等剂量和高剂量供试物A连续灌胃小鼠30天,能够显著提高小鼠血常规水平,具有显著的补血作用,同时,可以提高免疫器官的免疫活性,提高肝肾的抗氧化功能,修复应激损伤,且作用优于供试物B、C各剂量组;说明本发明所述的海参多肽阿胶膏具有滋补肝肾、养血的作用效果,且通过合理配伍增强了作用效果,安全无毒副作用。
效果评价:
按统计学原理,选100例该病的患者日常食用本发明海洋多肽阿胶膏。
该病的诊断标准:具有一些头晕目眩、眼干、易疲乏、肢体的麻木、皮肤的瘙痒、口燥、咽干、失眠多梦、胁肋部隐痛、遗精、腰酸、腰膝酸软、耳鸣,不孕、遗精、舌红苔少等的表现。
疗效标准:显效:临床症状及体征消失或明显减轻,理化检查明显改善,积分值下降大于2/3;有效:临床症状及体征减轻,理化检查有所改善,积分值下降在1/3~2/3之间;无效:临床症状及体征无改善,理化检查无明显变化,积分值下降小于1/3。
观察结果:总有效率为91%,其中有效为73%,显效为18%,无效9%。
通过以下典型病例进一步证明本发明的滋补效果:
病例1:
孙某,女,57岁,退休职工。头晕头痛5年,心悸气短,浑身乏力,腰腿酸软,偶伴肢体麻木,常感口干咽干,且眠差多梦健忘,中医诊断为肝肾阴虚,日常食用本发明海参多肽阿胶膏(实施例4),每日1次,每次100g,连续食用2个月,上述症状明显减轻,食用前积分41分,食用后积分14分,积分差27。疗效判定显效。
病例2:
谢某,男,59岁,干部。面色苍白,心悸、气短,乏力,不能久立,少寐多梦,免疫力下降,易感冒。中医诊断为肝肾亏损,精血不足,日常食用本发明海参多肽阿胶膏(实施例4),每日1次,每次100g,连续食用1个月,面色改善明显,心悸、气短、乏力症状明显减轻,睡眠状况显著提升,免疫力有所提高。治疗前积分39分,后积分21分,积分差18。疗效判定有效。
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (5)
1.一种滋补肝肾、养血安神海洋多肽阿胶膏,其特征在于,由以下组分按重量份数制备而成:水55-74份,阿胶9-15份,鲍鱼低聚肽4-12份,牡蛎低聚肽4-10份,蛹虫草3-8份,人参2-5份,酸枣仁2-10份,仙草2-5份。
2.根据权利要求1所述滋补肝肾、养血安神海洋多肽阿胶膏,其特征在于,由以下组分按重量份数制备而成:
水59份,阿胶12份,鲍鱼低聚肽6份,牡蛎低聚肽6份,蛹虫草4份,人参4份,酸枣仁6份,仙草3份。
3.根据权利要求1或2所述滋补肝肾、养血安神海洋多肽阿胶膏,其特征在于,所述鲍鱼低聚肽由以下方法制备而成:
①原料预处理:将整鲍鱼粉碎至10-20目,加入2-3倍量水,得鲍鱼匀浆液,备用;
②微生物发酵:取步骤①制备的鲍鱼匀浆液,按10-20:1:1的质量比加入复合菌液、葡萄糖;搅拌均匀,调节pH至4.5-7.5,保持温度28-32℃,发酵12-24h,得鲍鱼发酵液,备用;
③超声酶解:向步骤②得到的鲍鱼发酵液中加入5-8倍量水,NaOH调节pH至8.0-9.0,加入初始处理鲍鱼1%-2%倍量的复合碱性蛋白酶,加热升温至40-60℃,超声功率为500-700W,保温搅拌酶解3-5h,离心过滤收集酶解液,备用;
④灭菌、灭酶:将步骤③的酶解液煮沸15-20min灭菌、灭酶后进行0.5~1μm微滤膜过滤,去掉大分子杂质、细菌、霉菌,收集滤液,备用;
⑤脱色脱腥:将步骤④的滤液利用10~20nm纳滤膜过滤,去掉色素、蛋白等,滤液添加2-3%(w/v)812目颗粒活性炭脱腥处理,脱碳后收集液相,得精制液备用;
⑥浓缩干燥:将步骤⑤得到的精制液浓缩至质量分数30-40%,喷雾干燥,制得鲍鱼低聚肽。
4.根据权利要求3所述滋补肝肾、养血安神海洋多肽阿胶膏,其特征在于,所述步骤②中复合菌液为米曲霉种子液5-8份、枯草芽孢杆菌菌液2-5份;所述米曲霉种子液中的菌含量≥3×108cfu/mL,所述枯草芽孢杆菌菌液中的菌含量≥3×108cfu/mL。
5.权利要求1~4任一项所述滋补肝肾、养血安神海洋多肽阿胶膏的制备方法,其特征在于,步骤如下:
1)原料粉碎、浸泡:按组分称取蛹虫草、人参、酸枣仁、仙草,分别粉碎至10-20目,加入到6-10倍水中浸泡5-10h;
2)提取:将步骤1)浸泡后的蛹虫草、人参、酸枣仁、仙草放入提取罐中,加热到80-100℃,提取1-1.5h,过滤得第一次提取液;滤渣加入5-8倍水,加热到80-100℃,提取1-1.5h,过滤得第二次提取液;
3)浓缩定容:合并步骤2)两次提取液,于浓缩罐中浓缩至初始药材质量分数为7-23%,得定容液,备用;
4)提取液熬胶:取阿胶加入到步骤3)制备的提取定容液中,煮沸,搅拌熬煮10-15min;
5)配料制膏:按组分将鲍鱼低聚肽、牡蛎低聚肽混合均匀,缓慢加入到步骤4)的熬煮液中,边加入边搅拌,完全加入后继续搅拌15-20min,过程保温在80-99℃;
6)罐装灭菌:将步骤5)得到的膏液进行罐装,罐装温度保持在80-95℃,罐装量为容器的90-95%,密封,恒温20-30min进行灭菌;
7)冷却成型:冷却至常温;
8)包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911144450.7A CN110710678A (zh) | 2019-11-20 | 2019-11-20 | 一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911144450.7A CN110710678A (zh) | 2019-11-20 | 2019-11-20 | 一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110710678A true CN110710678A (zh) | 2020-01-21 |
Family
ID=69215371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911144450.7A Pending CN110710678A (zh) | 2019-11-20 | 2019-11-20 | 一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110710678A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111264862A (zh) * | 2020-02-10 | 2020-06-12 | 云南中科本草科技有限公司 | 一种抗疲劳组合物、其制备方法及抗疲劳药物或保健食品 |
CN111480817A (zh) * | 2020-05-15 | 2020-08-04 | 大洲新燕(厦门)生物科技有限公司 | 一种阿胶鲍鱼肽膏及其制备方法 |
WO2022179050A1 (zh) * | 2021-02-23 | 2022-09-01 | 广东海洋大学 | 一种防治酒精性肝损伤的组合物及其制备方法与应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103798576A (zh) * | 2012-11-15 | 2014-05-21 | 万玉洁 | 一种鲍鱼固元膏 |
CN107692214A (zh) * | 2017-11-13 | 2018-02-16 | 安徽生物肽产业研究院有限公司 | 一种提高免疫力作用的复合肽阿胶浆 |
CN108208830A (zh) * | 2018-03-09 | 2018-06-29 | 山东承御堂阿胶有限公司 | 一种牡蛎草本膏滋及其制备方法 |
CN108477565A (zh) * | 2018-03-11 | 2018-09-04 | 山东承御堂阿胶有限公司 | 一种灵芝仙草膏滋及其制备方法 |
CN109295146A (zh) * | 2018-11-07 | 2019-02-01 | 北京康宝利华生物科技有限公司 | 酶法鲍鱼酶法提取物及其制备方法 |
CN109452607A (zh) * | 2018-11-07 | 2019-03-12 | 北京康宝利华生物科技有限公司 | 包含鲍鱼酶法提取物的调味汁及其制备方法 |
CN109601993A (zh) * | 2017-09-30 | 2019-04-12 | 时传彬 | 一种补肾益气养血安神滋补膏及其制备工艺 |
-
2019
- 2019-11-20 CN CN201911144450.7A patent/CN110710678A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103798576A (zh) * | 2012-11-15 | 2014-05-21 | 万玉洁 | 一种鲍鱼固元膏 |
CN109601993A (zh) * | 2017-09-30 | 2019-04-12 | 时传彬 | 一种补肾益气养血安神滋补膏及其制备工艺 |
CN107692214A (zh) * | 2017-11-13 | 2018-02-16 | 安徽生物肽产业研究院有限公司 | 一种提高免疫力作用的复合肽阿胶浆 |
CN108208830A (zh) * | 2018-03-09 | 2018-06-29 | 山东承御堂阿胶有限公司 | 一种牡蛎草本膏滋及其制备方法 |
CN108477565A (zh) * | 2018-03-11 | 2018-09-04 | 山东承御堂阿胶有限公司 | 一种灵芝仙草膏滋及其制备方法 |
CN109295146A (zh) * | 2018-11-07 | 2019-02-01 | 北京康宝利华生物科技有限公司 | 酶法鲍鱼酶法提取物及其制备方法 |
CN109452607A (zh) * | 2018-11-07 | 2019-03-12 | 北京康宝利华生物科技有限公司 | 包含鲍鱼酶法提取物的调味汁及其制备方法 |
Non-Patent Citations (1)
Title |
---|
中国轻工业联合会: "牡蛎肽的功能特性及应用", 《中国食品报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111264862A (zh) * | 2020-02-10 | 2020-06-12 | 云南中科本草科技有限公司 | 一种抗疲劳组合物、其制备方法及抗疲劳药物或保健食品 |
CN111480817A (zh) * | 2020-05-15 | 2020-08-04 | 大洲新燕(厦门)生物科技有限公司 | 一种阿胶鲍鱼肽膏及其制备方法 |
WO2022179050A1 (zh) * | 2021-02-23 | 2022-09-01 | 广东海洋大学 | 一种防治酒精性肝损伤的组合物及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110710678A (zh) | 一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法 | |
CN103387899B (zh) | 一种红茶酒及其制造方法 | |
CN107319086A (zh) | 一种枸杞金丝皇菊压片糖果及其制备方法 | |
CN109123622A (zh) | 一种调理养生玫瑰花发酵酵素及其制备方法 | |
CN108991078A (zh) | 一种防控富贵病的桑叶食品及其制备方法 | |
CN101185463A (zh) | 减肥保健早餐奶 | |
CN108143974A (zh) | 解酒护肝丸 | |
CN106924548A (zh) | 一种缓解疲劳的药物及制备方法 | |
CN111467468A (zh) | 一种含人参、蛹虫草、生姜、枸杞子浓缩营养液及其制备方法 | |
CN111358922A (zh) | 温补肾阳改善寒性体质的中药组合物及其制备方法和应用 | |
CN116076710A (zh) | 一种具有抗衰美白功能的玫瑰本草酵素及其制备方法和应用 | |
CN110093239A (zh) | 一种诺丽配制酒及其制备方法 | |
CN102925313A (zh) | 滋补桂圆酒的酿造方法 | |
CN109757639A (zh) | 一种人参三元肽饮料及其制备方法 | |
CN109123621A (zh) | 一种可调节机体免疫功能抑制血糖升高的保健食品 | |
CN104783174A (zh) | 一种纯天然营养免疫保健固体饮料的配制方法 | |
CN108433108A (zh) | 一种六红素制剂及其制备方法 | |
CN101869164B (zh) | 一种零余子养颜茶 | |
CN104435648A (zh) | 一种食药两用的组合物及其用途和制备方法 | |
CN113749152A (zh) | 一种健康养生强身饮品及其制备方法 | |
CN113545405A (zh) | 一种速溶补血养颜茶及其制备方法 | |
CN106234699A (zh) | 一种清热宣化治疗发热的药茶及制备加工方法 | |
CN111870630A (zh) | 一种用于增加抵抗力和免疫力的药物配方及制备工艺 | |
CN109275914A (zh) | 黑木耳多肽功能食用组合物及其制备方法和应用 | |
CN112273653A (zh) | 一种双向改善胃肠道功能、减肥美容谷物果蔬组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200121 |